102 related articles for article (PubMed ID: 21573668)
21. Circumvention of platinum resistance: structure-activity relationship for homologous series of ammine/amine platinum(II) complexes in L1210 cell lines.
Yoshida M; Khokhar AR; Siddik ZH
Anticancer Drug Des; 1994 Oct; 9(5):425-34. PubMed ID: 7945726
[TBL] [Abstract][Full Text] [Related]
22. Ammine/amine platinum (II) complexes effective in vivo against murine tumors sensitive or resistant to cisplatin and tetraplatin.
Siddik ZH; Thai G; Yoshida M; Zhang YP; Khokhar AR
J Cancer Res Clin Oncol; 1994; 120(10):571-7. PubMed ID: 7929527
[TBL] [Abstract][Full Text] [Related]
23. Reduced drug accumulation as a major mechanism of acquired resistance to cisplatin in a human ovarian carcinoma cell line: circumvention studies using novel platinum (II) and (IV) ammine/amine complexes.
Loh SY; Mistry P; Kelland LR; Abel G; Harrap KR
Br J Cancer; 1992 Dec; 66(6):1109-15. PubMed ID: 1457352
[TBL] [Abstract][Full Text] [Related]
24. The relationships between glutathione, glutathione-S-transferase and cytotoxicity of platinum drugs and melphalan in eight human ovarian carcinoma cell lines.
Mistry P; Kelland LR; Abel G; Sidhar S; Harrap KR
Br J Cancer; 1991 Aug; 64(2):215-20. PubMed ID: 1892748
[TBL] [Abstract][Full Text] [Related]
25. Novel trans platinum complexes: comparative in vitro and in vivo activity against platinum-sensitive and resistant murine tumours.
Goddard PM; Orr RM; Valenti MR; Barnard CF; Murrer BA; Kelland LR; Harrap KR
Anticancer Res; 1996; 16(1):33-8. PubMed ID: 8615631
[TBL] [Abstract][Full Text] [Related]
26. Biotransformation of the platinum drug JM216 following oral administration to cancer patients.
Raynaud FI; Mistry P; Donaghue A; Poon GK; Kelland LR; Barnard CF; Murrer BA; Harrap KR
Cancer Chemother Pharmacol; 1996; 38(2):155-62. PubMed ID: 8616906
[TBL] [Abstract][Full Text] [Related]
27. Kinetics of tissue disposition of cis-ammine/cyclohexylamine-dichloroplatinum(II) and cisplatin in mice bearing FSaIIC tumors.
Yoshida M; Khokhar AR; Zhang YP; Thai G; Siddik ZH
Cancer Chemother Pharmacol; 1994; 35(1):38-44. PubMed ID: 7987975
[TBL] [Abstract][Full Text] [Related]
28. Acquisition of platinum drug resistance and platinum cross resistance patterns in a panel of human ovarian carcinoma xenografts.
Jones M; Siracky J; Kelland LR; Harrap KR
Br J Cancer; 1993 Jan; 67(1):24-9. PubMed ID: 8427780
[TBL] [Abstract][Full Text] [Related]
29. Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.
O'Neill CF; Koberle B; Masters JR; Kelland LR
Br J Cancer; 1999 Dec; 81(8):1294-303. PubMed ID: 10604725
[TBL] [Abstract][Full Text] [Related]
30. The role of murine tumour models and their acquired platinum-resistant counterparts in the evaluation of novel platinum antitumour agents: a cautionary note.
Goddard PM; Valenti MR; Harrap KR
Ann Oncol; 1991 Sep; 2(8):535-40. PubMed ID: 1793720
[TBL] [Abstract][Full Text] [Related]
31. The role of glutathione (GSH) in determining sensitivity to platinum drugs in vivo in platinum-sensitive and -resistant murine leukaemia and plasmacytoma and human ovarian carcinoma xenografts.
Goddard P; Valenti M; Kelland LR
Anticancer Res; 1994; 14(3A):1065-70. PubMed ID: 8074451
[TBL] [Abstract][Full Text] [Related]
32. The tissue distribution in BALB/c mice of C-14-labeled JM216, an orally active platinum antitumour compound.
Bates PI; Sharma HL; Murrer BA; McAuliffe CA
Cancer Chemother Pharmacol; 1996; 39(1-2):170-5. PubMed ID: 8995517
[TBL] [Abstract][Full Text] [Related]
33. Mini-review: discovery and development of platinum complexes designed to circumvent cisplatin resistance.
Kelland LR; Sharp SY; O'Neill CF; Raynaud FI; Beale PJ; Judson IR
J Inorg Biochem; 1999 Oct; 77(1-2):111-5. PubMed ID: 10626362
[TBL] [Abstract][Full Text] [Related]
34. New cisplatin analogues in development. A review.
Weiss RB; Christian MC
Drugs; 1993 Sep; 46(3):360-377. PubMed ID: 7693428
[TBL] [Abstract][Full Text] [Related]
35. Sensitivity to novel platinum compounds of panels of human lung cancer cell lines with acquired and inherent resistance to cisplatin.
Twentyman PR; Wright KA; Mistry P; Kelland LR; Murrer BA
Cancer Res; 1992 Oct; 52(20):5674-80. PubMed ID: 1327513
[TBL] [Abstract][Full Text] [Related]
36. Therapeutic and pharmacological studies of tetrachloro(d,l-trans)1,2-diaminocyclohexane platinum (IV) (tetraplatin), a new platinum analogue.
Rahman A; Roh JK; Wolpert-DeFilippes MK; Goldin A; Venditti JM; Woolley PV
Cancer Res; 1988 Apr; 48(7):1745-52. PubMed ID: 3162402
[TBL] [Abstract][Full Text] [Related]
37. Pharmacokinetics of satraplatin (JM216), an oral platinum (IV) complex under daily oral administration for 5 or 14 days.
Vouillamoz-Lorenz S; Buclin T; Lejeune F; Bauer J; Leyvraz S; Decosterd LA
Anticancer Res; 2003; 23(3C):2757-65. PubMed ID: 12926110
[TBL] [Abstract][Full Text] [Related]
38. The establishment, characterization and calibration of human ovarian carcinoma xenografts for the evaluation of novel platinum anticancer drugs.
Harrap KR; Jones M; Siracky J; Pollard LA; Kelland LR
Ann Oncol; 1990; 1(1):65-76. PubMed ID: 2078487
[TBL] [Abstract][Full Text] [Related]
39. New platinum agents. A comparison in ovarian cancer.
Kelland LR; McKeage MJ
Drugs Aging; 1994 Aug; 5(2):85-95. PubMed ID: 7981487
[TBL] [Abstract][Full Text] [Related]
40. Biochemical pharmacology of homologous alicyclic mixed amine platinum(II) complexes in sensitive and resistant tumor cell lines.
Yoshida M; Khokhar AR; Siddik ZH
Cancer Res; 1994 Jul; 54(13):3468-73. PubMed ID: 8012968
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
